FOR IMMEDIATE RELEASE Contact Information: Robert Siegfried VP, Finance and Administration 952.912.5400   More News   ( ‹ back to main article) November 14, 2007 Advanced Bio-Surfaces Announces New CEO November 6, 2007 The OrthoGlide® Medial Knee Implant Continues to be Accepted as an Alternative to Total Knee Replacement June 07, 2007 OrthoGlide® Medial Knee Implant Reports Over 200 Implants April 11, 2007 Advanced Bio-Surfaces® Receives Award for OrthoGlide® Medial Knee Implant May 25, 2006 Advanced Bio-Surfaces® Announces Initial Experiences of OrthoGlide® Medial Knee Implant February 15, 2006 Advanced Bio-Surfaces® Receives CE Mark for OrthoGlide® Medial Knee Implant February 8, 2006 Advanced Bio-Surfaces® Receives FDA Clearance to Market for OrthoGlide® Medial Knee Implant

Advanced Bio-Surfaces® Receives CE Mark for OrthoGlide® Medial Knee Implant New surgical treatment option now available in the European Community MINNEAPOLIS, February 15, 2006 /PRNewswire/ -- Advanced Bio-Surfaces, Inc. (ABS) an orthopedic implant developer and manufacturer, announced today the company has been notified that its Technical File for the OrthoGlide Medial Knee Implant fulfills the requirements of the European Union’s (EU) Medical Device Directive. The notification from the Notified Body, TÜV Product Services (Munich), allows Advanced Bio-Surfaces to immediately begin applying the CE mark to the OrthoGlide Medial Knee Implant for sale in the EU. The cobalt-chrome alloy composition of the innovative OrthoGlide implant has successfully passed functional and safety requirements. In addition, the implant’s unique engineering design provides positional stability without the use of rigid fixation methods. The OrthoGlide has a specially contoured geometry which functions to provide an open glide path and allows for the unconstrained motion of the femoral condyle, while requiring less tissue and bone removal than current surgical options. “Receiving the CE mark is another important milestone for Advanced Bio-Surfaces and the development of the OrthoGlide market. ABS is please with its achievement of obtaining FDA clearance to market and the CE mark,” said Dr. Jeff Felt, Chairman and CEO of Advanced Bio-Surfaces. “The receipt of the CE mark enables us to offer the OrthoGlide implant to more patients in need of a better option for osteoarthritis.” Dr. Klaus Lehrberger from Münich, Germany said,” With this approval, ABS has made significant progress towards providing international orthopedic surgeons and their patients a better solution.” Dr. Lehrberger continued, “For surgeons operating in the EU, the CE Mark is intended to ensure them and their patients of the product’s safety.” About Advanced Bio-Surfaces, Inc. ABS is a privately held company dedicated to the development of innovative joint repair products. The OrthoGlide Medial Knee Implant is the company’s first product and is intended for treatment of patients with moderate osteoarthritis of the medial compartment. For additional information contact Robert Siegfried at 952.912.5400.